it, or it, is a selective tyrosine kinase inhibitor of KIT and platelet derived growth factor receptor alpha indicated for the treatment of unresectable, metastatic gastrointestinal stromal tumors. It is one of the first medications available for the treatment of multidrug resistant cancers. it shares a similar mechanism with [ripretinib].  it was granted FDA approval on 9 January 2020. 
